title: Treatment of Newly Diagnosed Elderly Multiple Myeloma.
abstract: Multiple myeloma (MM) is a disease of the elderly, with a median age at diagnosis of approximately 70 years old, and more than 30 % of patients aged >75 years. This latter and very elderly population is going to significantly rise in the near future given the increase in life expectancy in Western countries, and, most importantly, global health status of elderly patients is improving, justifying appropriate treatments. Changes in treatment paradigm from the old melphalan-prednisone regimen used since the 1970s to its use as a backbone in a nontransplant setting since the late 1990s have highlighted different subgroups in elderly MM. Some "elderly" patients could be treated like transplant eligible patients, more likely those aged between 65 and the early 70; while a second group would rather be referred to current approved treatment regimens for the non-transplant setting. A dose-intensity approach seems reasonable for this group, aiming for the best response, eventually the complete response (CR) or even minimal residual disease (MRD). The advent of novel agents such as thalidomide, bortezomib, and most recently lenalidomide have allowed a major improvement in outcome as compared to historical combinations, and soon the novel class of monoclonal antibodies should help to further improve these patients' survival. Nonetheless, elderly patients are more susceptible to side effects and are often unable to tolerate full drug doses, and thus require lower dose intensity regimens, or novel drugs or combinations with more favourable safety profile. Recent developments in MM have focused on identifying these vulnerable patients through geriatric assessment and novel myeloma scoring system, including the notions of frailty, disability and comorbidities. Eventually, we have reached an era in which we should be able to provide individualized treatment strategies and drug doses-"tailored therapy"-to improve tolerability and optimize efficacy and ultimately survival for most elderly MM patients.
authors.affiliation: Service des maladies du sang, Hôpital Huriez, CHRU, Lille, France.
authors.forename: Guillemette
authors.initials: G
authors.lastname: Fouquet
authors.affiliation: Myeloma Unit, Division of Hematology, University of Torino, Turin, Italy.
authors.forename: Francesca
authors.initials: F
authors.lastname: Gay
authors.affiliation: Service des maladies du sang, Hôpital Huriez, CHRU, Lille, France.
authors.forename: Eileen
authors.initials: E
authors.lastname: Boyle
authors.affiliation: Myeloma Unit, Division of Hematology, University of Torino, Turin, Italy.
authors.forename: Sara
authors.initials: S
authors.lastname: Bringhen
authors.affiliation: Myeloma Unit, Division of Hematology, University of Torino, Turin, Italy.
authors.forename: Alessandra
authors.initials: A
authors.lastname: Larocca
authors.affiliation: Service des maladies du sang, Hôpital Huriez, CHRU, Lille, France.
authors.forename: Thierry
authors.initials: T
authors.lastname: Facon
authors.affiliation: Service d'Hématologie et Thérapie Cellulaire, CHU, La Milétrie, Poitiers, France. xavier.leleu@chu-poitiers.fr.
authors.forename: Xavier
authors.initials: X
authors.lastname: Leleu
authors.affiliation: Myeloma Unit, Division of Hematology, University of Torino, Turin, Italy.
authors.forename: Antonio
authors.initials: A
authors.lastname: Palumbo
mesh_terms: D000368:Aged; D006801:Humans; D009101:Multiple Myeloma / Q000628:therapy*
keywords: Elderly; Multiple myeloma; Newly diagnosed